Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (NAICS 42345)

A rollup primer. This is a short page: this NAICS industry is effectively identical to its single child industry, 423450, which carries the full detail.

1. Overview

NAICS code 42345 covers the merchant wholesalers — the distributors — who buy medical, dental, surgical, hospital, laboratory, and ophthalmic equipment and supplies, warehouse them, and resell them to hospitals, surgery centers, doctors' and dentists' offices, nursing homes, and increasingly to patients at home. "Merchant" wholesalers take title to the goods (they own the inventory), which distinguishes them from agents and brokers who never own what they sell. This is a large, essential, low-margin logistics business whose demand tracks health care utilization rather than the economic cycle — which makes it defensive, but whose economics are unforgiving: distributors live on thin spreads and win on scale, working-capital discipline, and logistics. The middle layer is not optional: about 90% of U.S. hospitals buy through commercial distributors rather than self-distributing.[1]

NAICS (the North American Industry Classification System) is the standard the U.S., Canada, and Mexico use to classify businesses. Codes get more specific as they get longer: the 5-digit "industry" 42345 sits directly above the 6-digit "national industry" 423450.

2. What's inside — and why this level equals its one child

A 5-digit NAICS industry can contain several 6-digit national industries. This one contains exactly one: 423450, which carries the identical name. When a 5-digit industry has a single 6-digit child, the two are definitionally the same economic activity — the U.S. simply did not subdivide it further. Every firm, dollar of sales, establishment, and worker counted at 42345 is also counted at 423450, and vice versa.

So this page exists only to name the level and hand you its own ground-truth statistics. The boundaries matter more than the internal structure here, because the biggest companies sit on the far side of them: pharmaceutical wholesaling is a separate code (NAICS 424210), making the devices is manufacturing (NAICS 339112/339113/339114/339115), eyeglass and contact-lens wholesaling is 423460, and delivering the care is the NAICS 62 health care sector. For the full treatment — scope and exclusions, the three distinct business models packed under one code, the investable companies, margins, demand drivers, regulation, consolidation, risks, and how to invest — read the child primer, NAICS 423450. Everything below is a compressed pointer to it.

3. Size (this level's rollup figures)

These are our federal ground-truth figures for 42345; because the level equals its one child, they are identical to the 423450 numbers.

The ~$125,000 average payroll per worker is high for a wholesale/logistics industry, reflecting a large, well-paid sales force and technical/clinical support staff alongside warehouse labor. The Small Business Administration's unusually generous 200-employee cutoff for this code is itself a signal that scale is the operating variable here.[4]

Undercount and boundary caveat. Wholesale distribution is captured reasonably well by the Economic Census — there is little hidden sole-proprietor activity here — so the $311.5 billion is a solid measure of this specific distribution slice. Beware of much smaller industry numbers that circulate alongside it: the Health Industry Distributors Association's panel tracked $57.5 billion of U.S. medical-supply distribution revenue in 2023 and $61 billion in 2025 (up 4.6% year over year), but that is a narrower channel measure and cannot be reconciled mechanically with the Census's broader establishment receipts.[5]

The distortion runs the other way for the household names, whose totals span several NAICS codes. Most of McKesson's, Cardinal Health's, and Cencora's revenue is pharmaceutical wholesaling (424210, a separate code) [6] — Cardinal Health reports roughly $227 billion company-wide but only about $12.6 billion in the medical segment that lands here.[7] And Medline's ~$28.4 billion in 2025 net sales spans both distribution (423450) and its own manufacturing (NAICS 339xxx).[8] Read the $311.5 billion as the size of the activity, not the combined revenue of the companies that dominate the headlines.

4. Investable universe (where value concentrates)

With a single child industry, there is no split of value "across children" to map — the whole investable universe is the one at 423450. In brief: there are only a handful of listed near-pure-play distributors — Medline (Nasdaq: MDLN, public since December 2025, ~$28.4 billion in 2025 net sales)[8] and Henry Schein (Nasdaq: HSIC, whose ~$11.1 billion distribution segment splits $6.9 billion dental and $4.3 billion medical)[9] — plus medical-distribution segments buried inside the diversified pharma-led giants Cardinal Health (NYSE: CAH, medical segment ~$12.6 billion)[7], McKesson (NYSE: MCK), and Cencora (NYSE: COR).

Private capital owns much of the rest, and increasingly buys into what remains public. Patterson Companies was taken private by Patient Square Capital for about $4.1 billion in 2025;[10] the former Owens & Minor distribution arm went to Platinum Equity, leaving the listed remainder renamed Accendra Health (NYSE: ACH), a home-medical-equipment company holding a 5% interest in the divested business;[11][12] and in June 2026 Apollo-managed funds paid $1.25 billion for roughly 13% of McKesson Medical-Surgical, implying about a $13 billion enterprise value for that unit while McKesson kept control.[13] See 423450 §4 for the full table.

5. How the money works

Distribution is a spread business: buy from a manufacturer, add a modest markup, deliver, and keep the cost of warehousing, delivering, and financing inventory below that markup. Gross margins are thin and vary sharply by channel — mid-single digits to low double digits in bulk hospital supply, versus the mid-20s to low-30s percent in value-added distribution to small dental, physician, and veterinary practices.[14] At the enterprise end the operating margin is a game of pennies at enormous volume: Cardinal Health's fiscal 2025 medical segment-profit margin was about 1.1%.[7] Medline's 2025 adjusted EBITDA margin of 12.2% looks like a different business because it partly is — roughly a third of its Medline-brand products are self-manufactured, so that figure blends manufacturing profit with distribution and is not a comparable "distribution margin."[8]

That contrast is the industry's central economic fact: own-brand (private-label) penetration is the biggest margin lever, because a distributor that makes its own products captures the manufacturer's margin on top of the distributor's. Full detail, including inventory-turn and working-capital math and the three business models (acute-care med-surg, value-added specialty, and home medical equipment), is in 423450 §5.

6. Demand drivers

Demand broadly tracks U.S. health care utilization, which reached about $4.9 trillion (17.6% of GDP) in 2023 and is projected to grow 5.4% a year through 2034 against 4.1% nominal GDP growth, lifting health spending from 18.0% of GDP in 2024 to 20.6% in 2034.[15] Supplies volume moves with it: hospital medical-and-surgical supply costs alone rose from about $40 billion to $57 billion between 2020 and 2025, roughly 8% a year.[16] The durable tailwinds are an aging population, rising surgical and procedure volumes, single-use disposables replacing reusables, and the shift of care from hospitals to outpatient and home settings — which changes which distributors win but keeps aggregate supply demand rising. HIDA's 2025 panel shows that reshuffling directly: sales rose 5.1% to hospitals and 2.3% to physician practices, but 9.3% to home care and 12.6% to treatment centers.[5] See 423450 §6.

7. Regulation

The U.S. Food and Drug Administration (FDA) regulates the devices, including the Unique Device Identification (UDI) system that flows through the distribution chain, plus postmarket tracking, recall, and safety-notification duties; state licensing governs distributors and durable-medical-equipment suppliers; and Centers for Medicare & Medicaid Services (CMS) reimbursement policy indirectly sets the price and volume ceiling for provider-facing and home-medical business. Note that the pharmaceutical track-and-trace regime (the Drug Supply Chain Security Act, or DSCSA) applies to drugs, not most devices — a common point of confusion.[17] Compliance load is not uniform: a pure domestic merchant wholesaler carries far less of it than a vertically integrated firm that also imports, relabels, repackages, or assembles kits.

Tariffs on Chinese-made commodity supplies are the live cost pressure. Section 301 duties on syringes and needles rose to 100% in 2024, with rubber medical gloves scheduled to reach 50% in 2025 and 100% in 2026 and certain masks and respirators stepping to 25% then 50%.[18] The magnitude is visible in filings: Medline disclosed an approximately $290 million adverse impact to 2025 pretax income from tariffs, with roughly $200 million more expected in 2026.[8] Full detail in 423450 §7.

8. Consolidation

The whole-industry statistics read "fragmented" — the top 4 firms hold only about 23.9% of revenue, the top 8 about 40.6%, the top 20 about 62.6%, and the top 50 about 75.7%, with a Herfindahl-Hirschman Index (HHI, a concentration measure where under 1,500 is "unconcentrated") of just 273.9.[2] But that headline is misleading: competition plays out inside distinct channels that are far more concentrated — an oligopoly (Medline, McKesson Medical-Surgical, Cardinal Health, Concordance) in hospital med-surg, and a duopoly (Henry Schein, Patterson) in dental, with thousands of regional and specialty distributors making up the long tail.

Buying power is concentrated even where selling isn't. More than 95% of U.S. hospitals purchase through group purchasing organizations, which are estimated to save members roughly 10–18%,[19] and the three largest — Vizient, HealthTrust, and Premier — cover over 75% of the market.[20] A consolidation wave crested in 2025: Patterson taken private for about $4.1 billion,[10] Owens & Minor's ~$10.7 billion distribution segment sold to Platinum Equity for $375 million,[11] and Medline's IPO raising $6.26 billion at a market value above $50 billion.[21] The through-line: the count of clean public distribution plays shrank even as the sector's biggest name arrived on public markets. See 423450 §8.

9. Risks

The core risk is margin compression from group-purchasing-organization leverage, customer consolidation, and commodity pricing.[19] Others: tariff and supply-chain shocks on Chinese-made commodities, where fixed-price contracts mean distributors absorb the hit before they can pass it through;[8][18] customer concentration and disintermediation (large systems buying direct, e-commerce entrants); interest-rate sensitivity on inventory- and receivables-heavy balance sheets; reimbursement cuts and softening elective-procedure volumes, which bite hardest in the dental and capital-equipment ends; and regulatory, product-liability, counterfeit/gray-market, and cybersecurity exposure. Full list in 423450 §9.

10. How to invest & outlook

For public-market investors, the shortest clean list is Medline (MDLN) and Henry Schein (HSIC), with diversified exposure available through the pharma-led giants (CAH, MCK, COR) — a defensive, cash-generative corner of health care best judged on cash generation and returns on capital rather than growth multiples. Two adjacent routes are worth knowing: Premier (Nasdaq: PINC) is exposure to the GPO side of the table rather than distribution,[20] and Accendra Health (NYSE: ACH) is now essentially a home-medical-equipment company with a 5% retained interest in the distribution business it sold.[12] Note also that Medline's public float is constrained by an insider lock-up into mid-2026, with its private-equity owners still large holders.[21]

For private-market investors, this is arguably more central: private equity owns some of the biggest names, and the long tail of regional and specialty distributors is a steady source of roll-up and buyout opportunity valued on cash flow, route density, and customer stickiness — with a diligence burden that is unusually operational (GPO contracts, supplier rebates, inventory aging, fill rates, freight terms, FDA role classification). The outlook: durable demand growth against structural margin pressure, favoring scaled distributors that manufacture their own products and run efficient logistics. Full how-to-invest detail, tickers, and the forward outlook are in 423450 §10.

---

Sources

Figures on this page draw on our federal ground-truth stats for NAICS 42345 and on the child primer for NAICS 423450; the full source list lives in that child primer.

1. Health Industry Distributors Association, "Majority of Hospital Systems Utilize Commercial Distribution," 2024 (~90% of hospitals use commercial distributors). https://www.hida.org/KnowledgeCenter/KnowledgeCenter/articles/majority-hospital-systems-utilize-commercial-distribution.aspx
2. U.S. Census Bureau, 2022 Economic Census — Concentration by Largest Firms (NAICS 423450 / 42345), 2022 (industry sales/receipts, firm count, CR4/CR8/CR20/CR50, HHI). https://www.census.gov/programs-surveys/economic-census.html
3. U.S. Census Bureau, County Business Patterns 2023 (NAICS 423450), 2023 (establishments, employment, annual and first-quarter payroll). https://www.census.gov/programs-surveys/cbp.html
4. U.S. Small Business Administration, Table of Size Standards (NAICS 423450 — 200 employees), 2023. https://www.sba.gov/document/support-table-size-standards
5. Health Industry Distributors Association, "Medical Products Sales Through Distribution Reach $61B in 2025," 2025 ($57.5B in 2023, $61B in 2025, +4.6%; channel growth rates by site of care). https://www.hida.org/KnowledgeCenter/KnowledgeCenter/articles/medical-products-sales-distribution-reach-61b-2025.aspx
6. IntuitionLabs, "US Drug Wholesalers: How McKesson, Cencora & Cardinal Control 90%+ of Distribution," 2025 (med-surg vs. pharma revenue split). https://intuitionlabs.ai/articles/drug-wholesaler-market-concentration
7. Cardinal Health, Fiscal Year 2025 Form 10-K, 2025 (medical segment ~$12.6B revenue, ~1.1% segment-profit margin; ~$227B company-wide). https://www.sec.gov/Archives/edgar/data/721371/000072137125000079/cah-20250630.htm
8. Medline Inc., 2025 Form 10-K, 2026 (net sales $28.4B, $3.5B adjusted EBITDA at 12.2% margin, ~one-third self-manufactured, ~$290M 2025 tariff impact and ~$200M expected 2026). https://www.sec.gov/Archives/edgar/data/2046386/000204638626000009/mdln-20251231.htm
9. Henry Schein, Inc., 2025 Form 10-K, 2026 (Global Distribution segment $11.1B: $6.9B dental, $4.3B medical). https://www.sec.gov/Archives/edgar/data/1000228/000100022826000013/hsic-20251227.htm
10. Latham & Watkins, "Patient Square Capital's Completed US$4.1 Billion Acquisition of Patterson Companies," 2025. https://www.lw.com/en/news/2025/04/latham-advises-on-patient-square-capital-completed-us4-1-billion-acquisition-of-patterson-companies
11. Owens & Minor, Inc., "Completes Sale of Products & Healthcare Services Business to Platinum Equity," Business Wire, December 2025 (FY2024 revenue ~$10.7B; $375M price). https://www.businesswire.com/news/home/20251231395792/en/Owens-Minor-Inc.-Completes-Sale-of-Products-Healthcare-Services-Business-to-Platinum-Equity
12. Accendra Health (formerly Owens & Minor), Form 8-K, December 2025 (renamed ACH; retained 5% interest in divested business). https://www.sec.gov/Archives/edgar/data/75252/000110465925122553/omi-20251216x8k.htm
13. McKesson Corporation, "McKesson Closes Strategic Investment with Apollo Funds for Minority Interest in Medical-Surgical Solutions," June 2026 ($1.25B for ~13% stake, ~$13B implied enterprise value). https://investor.mckesson.com/news/financial-news/2026/McKesson-Closes-Strategic-Investment-with-Apollo-Funds-for-Minority-Interest-in-Medical-Surgical-Solutions/default.aspx
14. CSIMarket, "Medical Equipment & Supplies Industry Profitability Ratios & Margins," Q1 2026 (industry gross/operating margin ranges). https://csimarket.com/Industry/industry_Profitability_Ratios.php?ind=804
15. Centers for Medicare & Medicaid Services, National Health Expenditures Fact Sheet, 2024 ($4.9T in 2023, 17.6% of GDP; 5.4% projected annual growth through 2034 vs. 4.1% nominal GDP; 18.0%→20.6% of GDP). https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet
16. Definitive Healthcare, "Annual Hospital Medical Supply Cost Changes," 2026 (med/surg supply costs $40B→$57B, 2020–2025). https://www.definitivehc.com/resources/healthcare-insights/changes-in-supply-costs-year-to-year
17. U.S. Food and Drug Administration, "Unique Device Identification System (UDI System)," 2013 rule / current (device regulation, GUDID; DSCSA applies to drugs, not devices). https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system
18. UNC Center for the Business of Health, "Tariffs on Medical Devices and Supplies: Healthcare Cost Implications," 2025 (Section 301 tariff schedule on syringes, gloves, PPE). https://cboh.unc.edu/publication/tariffs-on-medical-devices-and-supplies-healthcare-cost-implications/
19. Vizient, Inc., "Hospitals and patients nationwide benefit from Group Purchasing Organization collaboration," 2022 (>95% of hospitals use GPOs; 10–18% savings). https://www.vizientinc.com/insights/all/2022/hospitals-and-patients-nationwide-benefit-from-group-purchasing-organization-collaboration
20. Definitive Healthcare, "Top 10 GPOs by Staffed Beds in U.S. Hospitals," 2024 (Vizient, HealthTrust, Premier ≈ 75%+ of market). https://www.definitivehc.com/blog/top-10-gpos-by-staffed-beds
21. CNBC, "Medline debuts on Nasdaq after biggest IPO of 2025," December 2025 (IPO raised $6.26B; market value above $50B; lock-up and PE ownership). https://www.cnbc.com/2025/12/17/medline-debuts-nasdaq-biggest-ipo-2025.html

For the complete numbered Sources list (32 references covering company filings, GPO market share, tariff schedules, FDA rules, and industry economics), see the child primer, NAICS 423450.